R&D Spending Showdown: Eli Lilly and Company vs Dr. Reddy's Laboratories Limited

Pharma Giants' R&D Spending: A Decade of Innovation

__timestampDr. Reddy's Laboratories LimitedEli Lilly and Company
Wednesday, January 1, 2014124020000004733600000
Thursday, January 1, 2015174490000004796400000
Friday, January 1, 2016178340000005243900000
Sunday, January 1, 2017195510000005281800000
Monday, January 1, 2018182650000005051200000
Tuesday, January 1, 2019156070000005595000000
Wednesday, January 1, 2020154100000006085700000
Friday, January 1, 2021165410000007025900000
Saturday, January 1, 2022174820000007190800000
Sunday, January 1, 2023193810000009313400000
Monday, January 1, 20242287300000014271000000
Loading chart...

Unlocking the unknown

R&D Spending: A Tale of Two Giants

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. Over the past decade, Eli Lilly and Company and Dr. Reddy's Laboratories Limited have been at the forefront of this race. From 2014 to 2023, Dr. Reddy's consistently outspent Eli Lilly, with R&D expenses peaking at an impressive 22.9 billion in 2024. In contrast, Eli Lilly's R&D spending showed a steady increase, reaching 9.3 billion in 2023, marking a 97% growth from 2014. This trend highlights Dr. Reddy's aggressive investment strategy, while Eli Lilly's gradual increase reflects a more measured approach. The data for 2024 is incomplete for Eli Lilly, suggesting a potential shift in strategy or reporting. As these companies continue to innovate, their R&D investments will be crucial in shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025